CA Patent

CA3248817A1 — Sustained release pharmaceutical composition of upadacitinib

Assigned to Renata Pharmaceutical Ireland Ltd · Expires 2023-07-27 · 3y expired

What this patent protects

Disclosed herein is a sustained release pharmaceutical composition of upadacitinib and process for preparing the same, wherein said pharmaceutical composition comprising therapeutically effective amount of upadacitinib and pharmaceutically acceptable adjuvants, and wherein the co…

USPTO Abstract

Disclosed herein is a sustained release pharmaceutical composition of upadacitinib and process for preparing the same, wherein said pharmaceutical composition comprising therapeutically effective amount of upadacitinib and pharmaceutically acceptable adjuvants, and wherein the composition is free of polymer.

Drugs covered by this patent

Patent Metadata

Patent number
CA3248817A1
Jurisdiction
CA
Classification
—
Expires
2023-07-27
Drug substance claim
No
Drug product claim
No
Assignee
Renata Pharmaceutical Ireland Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.